News and media

AACMC Meeting 21 discusses medicinal cannabis prescribing practices, proposed legislative reforms, driving laws, patient safety and regulatory developments.

Information about updated medicinal cannabis licence and permit variation forms, revised fees and charges, and interim application arrangements.

Updated guidance on Australia's regulation of MDMA and psilocybine, including import, export, manufacturing and prescribing requirements.

Find out about the new fees and charges for the Medicinal Cannabis Scheme starting in August 2023.

The ODC has issued an infringement notice to the New South Wales-based company ABC CAN Pty Ltd for alleged security failures at its cannabis cultivation site.

AACMC Meeting 20 discusses medicinal cannabis access for veterans, GP education initiatives, patient safety and regulatory enforcement updates.

Learn about the review of Medicinal Cannabis Program fees and charges and proposed changes affecting licence and permit holders.

The redesigned ODC website delivers improved search, navigation and user-focused transaction pages to make information easier to find.

AACMC Meeting 19 discusses compassionate access, medicinal cannabis evidence for pain, prescribing education and concerns about paediatric use.

The Office of Drug Control within the Department of Health and Aged Care has issued Queensland-based Tikun Oceana Pty Ltd an infringement notice. 

AACMC Meeting 18 discusses medicinal cannabis prescribing, Delta-8 THC risks, road safety, product regulation and patient access developments.

ODC announces the suspension of Rapid Growth Pty Ltd's medicinal cannabis licences and permits under the Narcotic Drugs Act 1967.

AACMC Meeting 17 highlights medicinal cannabis licensing reforms, new compliance measures, prescribing pathway changes and Council achievements.

The Amendment Act provides for amendments to the Narcotic Drugs Act 1967 to support an innovative Australian medicinal cannabis industry for the benefit of Australian patients.

AACMC Meeting 16 discusses medicinal cannabis compliance, patient access pathways, low-dose CBD rescheduling and industry priorities.

AACMC Meeting 15 discusses medicinal cannabis compliance, CBD rescheduling, patient access trends, industry challenges and regulatory developments.

Introduction of the Narcotic Drugs Amendment (Medicinal Cannabis) Bill 2021.

Australia’s 2020 vote at the Commission on Narcotic Drugs on WHO recommendations for cannabis scheduling and related substances.

Cost recovery arrangements for cannabis-related manufacture licences and permits commenced on 1 November 2020.

AACMC Meeting 14 discusses medicinal cannabis clinic growth, advertising compliance, licensing reforms and increasing SAS approvals.

From 1 November 2020, subject to formal approval from the Federal Executive Council, cost recovery arrangements will be extended to cannabis-related manufacture licences and permits under the Medicinal Cannabis Scheme.

AACMC Meeting 13 discusses medicinal cannabis access for veterans, THC roadside testing, pharmacist guidance and regulatory developments.

Information on changes to Medicinal Cannabis Scheme fees and charges and their impact on licence and permit holders.

Joint media release - Department of Health (ODC) and Australian Border Force.

AACMC Meeting 12 discusses medicinal cannabis access, Senate Inquiry outcomes, COVID-19 regulatory measures and growing patient demand.